Sinotherapeutics (688247)2025-01-22 10:35Revenue Forecast - The company expects 2024 annual revenue to be between 451.17 million and 541.40 million CNY, representing a year-over-year increase of 50% to 81%[3]. - In 2023, the company achieved a revenue of 299.87 million CNY and a net profit of 61.07 million CNY[5]. - The significant growth in revenue is attributed to the company's focus on domestic and international sales and increased income from major product sales and equity sharing[6]. Profit Forecast - The projected net profit attributable to the parent company for 2024 is expected to be between 115.41 million and 138.49 million CNY, an increase of 89% to 127% compared to the previous year[3]. - The net profit attributable to the parent company after deducting non-recurring gains and losses is estimated to be between 103.20 million and 123.84 million CNY, reflecting a year-over-year increase of 117% to 161%[3]. CMO Revenue - The company has seen a notable increase in CMO revenue due to the commercialization of products from CRO/CMO clients[6]. Financial Data and Audit - The financial data in the performance forecast has not been audited by a registered accountant[4]. - Investors are advised that the forecast data is preliminary and the final audited financial data will be disclosed in the 2024 annual report[8]. - As of the announcement date, the company has not identified any major uncertainties affecting the accuracy of the performance forecast[7]. Announcement Details - The announcement was made by the board of directors on January 23, 2025[10].